Will Cardiff Oncology stock go up?

According to Danelfin AI, Cardiff Oncology has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.51%) is +1.68% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Cardiff Oncology stock?

The Cardiff Oncology target price is $1.29 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Cardiff Oncology stock right now?

Cardiff Oncology has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.51%) is +1.68% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Cardiff Oncology stock is a good buy .

Is Cardiff Oncology undervalued right now?

Based on analysts, the average price target downside for Cardiff Oncology is 0.00% (1Y). According to Danelfin AI, Cardiff Oncology has today an AI Score of 5/10 (Hold Rating).

What was the price range of Cardiff Oncology stock over the past 12 months?

The Cardiff Oncology stock price range over the past 12 months has been $1.18 - $4.45.

What is going on with Cardiff Oncology stock in the last 3 months?

The Cardiff Oncology stock performance in the last quarter has been -19.87%.

Does Cardiff Oncology offer dividend payments?

No, Cardiff Oncology does not currently pay dividends.

What is the current market capitalization of Cardiff Oncology?

Cardiff Oncology's market cap is $86.83M, as of 2026-07-03 08:00.

Cardiff Oncology Inc (CRDF) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CRDF AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+3.00%
Direction and strength of recent price movements
Earnings Quality+1.78%
Stability and reliability of reported earnings
Volatility+0.55%
How much the stock price tends to fluctuate

Valuation-1.67%
How the stock is priced relative to its fundamentals
Profitability-1.38%
Profitability and operating efficiency metrics
Sentiment-0.60%
How analysts and the market view the stock

CRDF probability advantage of beating the market (3M):

+1.68%

Sentiment

Cardiff Oncology (CRDF) has a Sentiment Score of 4/10 because, according to only sentiment analysis, it has a probability advantage of -2.43% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.04%) and the probability of CRDF (47.62%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s sentiment analysis.

Average probability of any US-listed stock of beating the market (3M)50.04%
CRDF probability advantage of beating the market (only sentiment, 3M)-2.43%
CRDF probability of beating the market (3M)47.62%

CRDF probability advantage of beating the market (only sentiment, 3M): -2.43%

The AI-powered sentiment analysis of Cardiff Oncology (CRDF) is only based on the 27 sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CRDF:

Type	Alpha Signal	Probability Advantage Impact (3M)
Sentiment	Upgrade to Pro to unlock	-3.68%
Sentiment	Upgrade to Pro to unlock	-1.91%
Sentiment	Upgrade to Pro to unlock	+1.50%
Sentiment	Upgrade to Pro to unlock	+1.16%
Sentiment	Upgrade to Pro to unlock	-1.13%
Sentiment	Upgrade to Pro to unlock	+1.10%
Sentiment	Upgrade to Pro to unlock	-0.42%
Sentiment	Upgrade to Pro to unlock	+0.42%
Sentiment	Upgrade to Pro to unlock	+0.38%
Sentiment	Upgrade to Pro to unlock	+0.37%
Sentiment	Upgrade to Pro to unlock	-0.29%
Sentiment	Upgrade to Pro to unlock	+0.29%
Sentiment	Upgrade to Pro to unlock	+0.20%
Sentiment	Upgrade to Pro to unlock	-0.15%
Sentiment	Upgrade to Pro to unlock	-0.14%

Rest of Alpha Signals: -0.12%

CRDF probability advantage of beating the market (only sentiment, 3M)Total:-2.43%
CRDF Sentiment Score

Significant changes Vs previous day

CRDF Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$1.29
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

CRDF Proven Hold Signal & Price Forecast

This is the price chart for CRDF from January 2, 2026 until today. The chart indicates, in yellow, the 84 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CRDF Average Past Performance & Win Rate

Three months after its 1383 Hold signals since July 2026, CRDF had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

1383 Past CRDF Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+65.09%
Average Alpha				+49.96%
Win Rate (% Positive Perf.)				39.62%
% Positive Alpha				34.06%

CRDF Frequently Asked Questions

Will Cardiff Oncology stock go up?
According to Danelfin AI, Cardiff Oncology has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.51%) is +1.68% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Cardiff Oncology stock?
Is it a good time to buy, sell, or hold Cardiff Oncology stock right now?
Is Cardiff Oncology undervalued right now?
What was the price range of Cardiff Oncology stock over the past 12 months?
What is going on with Cardiff Oncology stock in the last 3 months?
Does Cardiff Oncology offer dividend payments?
What is the current market capitalization of Cardiff Oncology?

Cardiff Oncology Inc Company Profile

Cardiff Oncology, Inc., is a clinical-stage biotechnology enterprise based in California that dedicates its innovative efforts to devise advanced therapeutic strategies for various types of cancer. The flagship drug candidate under their belt is Onvansertib, an orally-administered selective Polo-like Kinase 1 Inhibitor. This revolutionary intervention is primarily targeted towards treating an array of solid tumor cancers alongside KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer. The enterprise also actively harnesses its scientific prowess for investigator-initiated trials, primarily focusing on combating triple negative breast cancer and small cell lung cancer.

Moreover, Cardiff Oncology also harbors TROV-054 in its medical artillery - a drug currently in phase 1b/2 that's to be conjoined with FOLFIRI and Bevacizumab for optimum results. The company’s key constituency consists mainly of pharmaceutical manufacturers who require the novel treatments it develops.

Tracing back its lineage to when it was formerly known as Trovagene, Inc., the organization decided to transition itself with the new identity of Cardiff Oncology, Inc. in May 2012. This has been ever since it initially laid down its institutional roots back in 1999. Presently, the operational epicenter of Cardiff Oncology lies nestled within the heart of San Diego, California.

Sector:
Country:United States
Industry:
Address:11055 Flintkote Ave, San Diego
Employees:31
Website:cardiffoncology.com

Pros

Proprietary drug candidate with patent protection

Addressing unmet medical needs in oncology

Potential for high operating leverage post-approval

Platform potential for PLK1 inhibition

Attractive target for strategic partnerships

Cons

High clinical trial failure rates

Substantial capital requirements for development

Intense regulatory hurdles for market approval

Competition from established oncology pipelines

Dependency on a single primary drug candidate

Company	AI Score	Compare
BGMSCyclacel Pharmaceuticals Inc
CLRBCellectar Biosciences Inc
ONCYOncolytics Biotech Inc
ALXOALX Oncology Holdings Inc
PYXSPyxis Oncology Inc

Company	AI Score	Compare
BGMSCyclacel Pharmaceuticals Inc
CLRBCellectar Biosciences Inc
ONCYOncolytics Biotech Inc
ALXOALX Oncology Holdings Inc
PYXSPyxis Oncology Inc

CRDF Stock AI Analysis